Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 7, 2014; 20(9): 2352-2357
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2352
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2352
Optimum chemotherapy in the management of metastatic pancreatic cancer
Marwan Ghosn, Hampig Raphael Kourie, Fadi El Karak, Colette Hanna, Joelle Antoun, Dolly Nasr, Department of Oncology, Faculty of Medicine, Saint Joseph University, Beirut 166830, Lebanon
Author contributions: Ghosn M initiated the review; Ghosn M and Kourie HR performed the review and wrote and analyzed the data; Ghosn M, Kourie HR, El Karak F, Hanna C, Antoun J, and Nasr D reviewed and commented on the paper and provided final approval.
Correspondence to: Marwan Ghosn, MD, Department of Oncology, Faculty of Medicine, Saint Joseph University, Monot St, Beirut 166830, Lebanon. mghosn.hdf@usj.edu.lb
Telephone: +961-1-3226842 Fax: +961-1-1613397
Received: October 28, 2013
Revised: January 3, 2014
Accepted: January 14, 2014
Published online: March 7, 2014
Revised: January 3, 2014
Accepted: January 14, 2014
Published online: March 7, 2014
Core Tip
Core tip: This paper will be the newest study with the most recent updates in the treatment of metastatic pancreatic cancer. After a brief review of the different treatments for metastatic pancreatic cancer, the current treatment options are discussed, as well as novel therapies and approaches in the future.